Lonza in the news

Lonza is shifting investments abroad due to foreign countries' preference for locally sourced medicines, challenging Switzerland's pharma sector.

Swiss stocks rose modestly with Lonza shares up 4.3% after a key board nomination, Novartis announced positive clinical trial results for a kidney drug, and Sika acquired a Turkish adhesive company.

Lonza's stock declined slightly to CHF 510.00, with future earnings and dividend payouts projected positively by analysts.

Lonza's stock price fell by 0.8% to 510.00 CHF, trading near its 52-week low and with analysts projecting future earnings growth.

Stephen Fry nominated for Lonza's Board of Directors, bringing extensive HR and pharma experience.

Lonza's stock dipped 0.7% midday amid a broader SMI decline, trading below its recent 52-week high with upcoming Q2 earnings and a raised dividend forecast.

Lonza is selling its capsule business below expectations, leading to a major write-down and reduced goodwill.

Lonza plans to sell its capsule and dietary supplements business for over 2.3 billion Swiss francs, with the deal closing by late 2026.

Lonza reported better-than-expected revenue and profit, but its stock fell despite a positive outlook and attractive valuation.

Lonza is selling its Capsules & Health Ingredients business to Lone Star Funds for CHF 2.3 billion, retaining 40% ownership and focusing on its CDMO strategy.

Lonza's stock declined 3.7% to 480.80 CHF on SIX SX, with trading volume of 125,452 shares.

Lonza anticipates significant revenue and profit growth in 2025, with investor focus on new business impulses and potential sale of its capsule segment.

Lonza's stock dipped slightly midday, trading below its 52-week high, with analysts forecasting higher dividends and earnings for 2026.

Lonza's stock slightly declined to 537.20 CHF with expected dividend growth and upcoming quarterly earnings reports.

Lonza's stock rose 0.7% to 542 CHF, with analysts forecasting higher dividends and earnings for 2026.

Lonza's new collaboration with Iconovo on inhalable biologics supports its long-term growth in biologics manufacturing but does not alter near-term capacity and execution risks.

Lonza updates its Board of Directors with new appointments and resignations, including Sami Atiya joining and Claudia Süssmuth-Dyckerhoff becoming vice-chairwoman.

Lonza's strong 2025 results, boosted by its California facility and new customers, led to a 2.5% stock rise despite slightly conservative 2026 guidance.

Lonza's 2025 revenue and profits surged due to acquiring Roche's California facility, with strong growth and margin improvements expected to continue.

Lonza surpassed 2025 financial targets with strong growth in pharmaceutical manufacturing, plans further revenue and margin increases, and is focusing investments globally while divesting non-core businesses.